New triple therapy could simplify h. pylori treatment
NCT ID NCT07358130
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two 14-day antibiotic treatments for Helicobacter pylori infection, a common stomach bug that can cause ulcers. The triple therapy uses bismuth, amoxicillin, and vonoprazan, while the quadruple therapy adds rabeprazole, tetracycline, and metronidazole. Researchers will check which treatment works better and is safer in 552 infected adults, and also look at how antibiotic resistance and genetics affect success.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vonoprazan, bismuth, amoxicillin, rabeprazole, tetracycline, metronidazole
What this could lead to
If successful, this could show that a simpler triple therapy works as well as the standard quadruple therapy for treating H. pylori infection.
What could go wrong
This is a single-site trial with 552 participants, so results may not apply to everyone. Antibiotic resistance could reduce effectiveness, and side effects like stomach upset are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HELICOBACTER PYLORI INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kaohsiung Medical University Hospital
RECRUITINGKaohsiung City, 807, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••